Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks ...

Outside of HIV, Gilead's oncology franchise ended the year in the growth category, as well. The company's cancer treatments pulled down $843 million in fourth-quarter sales, representing a 10% ...

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Gilead Sciences has defied analysts’ expectations ... The CEO pointed to updated phase 1 data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium on Saturday ...

Gilead's diversified growth includes significant gains in oncology and liver disease, with Trodelvy and Livdelzi showing strong sales and robust potential for growth. 2025 milestones include ...

Gilead Sciences delivered strong 2024 results, driven by robust HIV and oncology performance. The anticipated mid-2025 launch of lenacapavir positions the company for growth despite headwinds from ...

Gilead Sciences specializes in developing antiviral drugs that treat HIV, hepatitis B, hepatitis C, and influenza. Recently, it has focused on expanding its oncology portfolio. The company views ...

Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back ...